These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 20920851)

  • 21. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Guidelines for prevention of febrile neutropenia].
    Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
    Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.
    Esser M; Brunner H
    Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.
    Silvestris N; Del Re M; Azzariti A; Maiello E; Lombardi L; Cinieri S; Guarini A; Brunetti AE; Delcuratolo S; De Vita F; Pisconti S; Danesi R; Colucci G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S111-7. PubMed ID: 22443211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agents under investigation for the treatment and prevention of neutropenia.
    Huston A; Lyman GH
    Expert Opin Investig Drugs; 2007 Nov; 16(11):1831-40. PubMed ID: 17970641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
    Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
    Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.
    Ratti M; Tomasello G
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):15-24. PubMed ID: 25409861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peg-filgrastim and cabazitaxel in prostate cancer patients.
    Di Lorenzo G; DʼAniello C; Buonerba C; Federico P; Rescigno P; Puglia L; Ferro M; Bosso D; Cavaliere C; Palmieri G; Sonpavde G; De Placido S
    Anticancer Drugs; 2013 Jan; 24(1):84-9. PubMed ID: 23044721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.
    Fust K; Parthan A; Maschio M; Gu Q; Li X; Lyman GH; Tzivelekis S; Villa G; Weinstein MC
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):39-52. PubMed ID: 28064553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia.
    Cappozzo C
    Oncol Nurs Forum; 2004 May; 31(3):569-76. PubMed ID: 15146222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of granulocyte-colony stimulating factor(G-CSF)in patients with cancer at high risk of febrile neutropenia on the basis of high age and complications, recommendations for patients receiving radiotherapy, and adverse events because of G-CSF].
    Hanada N; Tanaka S; Takahata T; Sato A
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):702-6. PubMed ID: 25129083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
    Aapro M; Crawford J; Kamioner D
    Support Care Cancer; 2010 May; 18(5):529-41. PubMed ID: 20191292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Present and future indications of G-CSF in breast cancer].
    Chevallier B
    Pathol Biol (Paris); 1993 Jan; 41(1):47. PubMed ID: 7686285
    [No Abstract]   [Full Text] [Related]  

  • 38. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.
    Morstyn G; Foote M; Perkins D; Vincent M
    Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
    Watanabe T
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.